预约演示
更新于：2026-01-12
Zinc Acetate
醋酸锌
更新于：2026-01-12
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-01-28), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C4H12O6Zn |
InChIKeyXOPBGQMRHYOLQZ-UHFFFAOYSA-N |
CAS号5970-45-6 |
关联
60
项与 醋酸锌 相关的临床试验CTR20254415
醋酸锌片人体生物等效性研究。
ACTRN12624001206516
Evaluating the impact of zinc supplementation on the incidence of respiratory infections in COPD patients
CTR20251603
醋酸锌片在健康研究参与者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
100 项与 醋酸锌 相关的临床结果
登录后查看更多信息
100 项与 醋酸锌 相关的转化医学
登录后查看更多信息
100 项与 醋酸锌 相关的专利（医药）
登录后查看更多信息
149,336
项与 醋酸锌 相关的文献（医药）2026-01-01NANO
Regeneration of Commercial SCR Catalyst Deactivated by Arsenic Poisoning Using a Green and Recyclable Solvent
作者: Qin, Hengfei ; Zhang, Hongyu ; Jiang, Jie ; Shi, Weiwei ; Chen, Shuhao ; Luo, Jing ; Fang, Haifeng ; Cheng, Long ; Meng, Juan
Selective catalytic reduction (SCR) is widely recognized as an effective method for denitrifying emissions in coal-fired power plants due to its straightforward application. However, a significant challenge arises from the degradation of catalysts used in these systems over time, mainly due to poisoning from arsenic. In our research, we introduce an eco-friendly technique that leverages hydrated acidic deep eutectic solvents (HDES) to extract arsenic from spent SCR catalysts. Our results demonstrate that the combined effects of the Lewis acid in ZnCl
2
, acting as a hydrogen bond acceptor (HBA) and the Brønsted acid site in H
3
PO
4
, acting as a hydrogen bond donor (HBD), along with 40% water, can achieve a remarkable arsenic removal rate of 98.11%. Furthermore, the regenerated catalyst exhibits an enhanced efficiency of 60.5% in the SCR of NO. Crucially, this approach preserves the structural integrity of the catalyst, marking it as a viable and sustainable option for the regeneration of spent SCR catalytic materials. This method not only enhances the removal efficiency of arsenic but also contributes to restoring the operational capabilities of the utilized catalysts.
2026-01-01YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Early Intervention by a Ward Pharmacist for the Hyperzincemia Caused by Zinc Oxide Ointment in a Infant with Diaper Dermatitis: A Case Report
Article
作者: Kitamura, Souya ; Yasugi, Misaki ; Otobe, Yutaka ; Konishi, Tomomi ; Uchizono, Hiromasa ; Asai, Yuki ; Takeuchi, Masaki ; Ooi, Hayahide ; Takahashi, Masaaki
Although zinc oxide ointment is commonly used to treat diaper dermatitis in infants, there exists limited evidence of pharmacists suspecting hyperzincemia due to zinc oxide ointment and early intervention for mitigation of severity. This case study is female infant who was born at 27 weeks and 1 d of gestation and weighing 542 g. On postnatal 49 d, the serum zinc concentration was 65 µg/dL. Thereafter, treatment with oral zinc acetate hydrate (2 mg/kg/d) began on 56 d for ameliorating hypozincemia. Zinc oxide ointment was administered on 86 d as a treatment for diaper dermatitis. Despite of attaining hyperzincemia (427 µg/dL), treatment with zinc acetate hydrate and zinc oxide ointment continued because diarrhea and nausea had not developed. On 105 d, the serum zinc concentration was 199 µg/dL and the dermatitis conditions showed a marked improvement. Consequently, the pharmacist considered that zinc oxide ointment might have contributed to the hyperzincemia and consulted with the physician. Subsequently, both the zinc acetate hydrate and zinc oxide ointment were discontinued. Although zinc acetate hydrate was restarted on 114 d, serum zinc concentration was 101 µg/dL on 128 d. The Naranjo Adverse Drug Reaction Probability Scale score was 9 points, which is categorized as "definitive." Administration of zinc oxide ointment to diaper dermatitis with decrease skin barrier may have increased percutaneous absorption of zinc, resulting hyperzincemia. The pharmacist may be able to conduct early intervention for hyperzincemia by monitoring not only serum zinc concentration but also changes in the dermatitis conditions in infant patients.
2025-12-31Italian Journal of Animal Science
Alpine pasture herbs redirected hydrogen towards alternative sinks, inhibiting methane production:
in vitro
study
作者: Dallavalle, Giulia ; Currò, Sarah ; Amalfitano, Nicolò ; Vrhovsek, Urska ; Angeli, Andrea ; Tagliapietra, Franco ; Nikolić, Nebojša ; Massaro, Selene ; Franciosi, Elena ; Andersen, Jonas Bylov Hedegaard ; Bailoni, Lucia
The impact of six alpine herbs (Alchemilla vulgaris L., Sanguisorba officinalis L., Tanacetum vulgare L., Cicerbita alpina (L.) Wallr., Galium odoratum (L.) Scop., and Sisymbrium officinale (L.) Scop.), was compared with grass hay on rumen degradability and fermentation parameters.The seven plants were fermented using an automatic in vitro system to evaluate the kinetics of gas production (GP), degraded dry matter (dDM) and fermentation end products [volatile fatty acids (VFA), carbon dioxide, methane, and hydrogen].Gas and methane productions were also computed from VFA using specific stoichiometric relationships.The partitioning factor (PF: ratio between dDM and GP) was calculated as an index of microbial growth.Compared to grass hay, the alpine herbs exhibited lower degradability (on average -12.8%) due to their high lignified fiber content.The alpine herbs also increase the PF (9.1%), suggesting a reduction in microbial growth efficiency, and altered the VFA profile by increasing the proportion of acetic acid (9.9%) at the expense of propionic (-11.9%) and n-butyric acids (-19.4%).Stoichiometric relationships typically associate these variations with an increase in methane proportion.However, this was not observed; in fact, Sanguisorba officinalis L. (-15.0%) and Galium odoratum L. Scop. (-13.9%) reduced methane productionThe discrepancy between the measured and expected methane production indicates that part of the hydrogen, not used for methane synthesis, was redirected to alternative sinks such as reductive acetogenesis.This change in the fermentation profile appears to be modulated by bioactive compounds present in the medicinal herbs, which are potentially found in grazing pastures.
100 项与 醋酸锌 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺锌 | 日本 | 2008-01-25 | |
| 肝豆状核变性 | 美国 | 1997-01-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 缺乏疾病 | 临床3期 | 日本 | 2015-01-01 | |
| 传染性红斑 | 临床3期 | - | 2004-10-01 | |
| 肌萎缩侧索硬化 | 临床1期 | 美国 | 2011-11-30 | |
| 糖尿病肾病 | 临床前 | 日本 | 2014-09-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 48 | (Control Group) | 餘齋鬱餘選膚顧網糧襯(夢遞鏇鬱膚蓋顧憲構網) = 觸鬱網顧艱簾範醖鏇願 範淵獵廠醖積獵艱獵衊 (衊衊餘簾網膚淵簾鏇簾, 16.5) 更多 | - | 2025-01-28 | ||
(EmoLED Group) | 餘齋鬱餘選膚顧網糧襯(夢遞鏇鬱膚蓋顧憲構網) = 顧積繭願廠範願糧窪淵 範淵獵廠醖積獵艱獵衊 (衊衊餘簾網膚淵簾鏇簾, 30.0) 更多 | ||||||
N/A | - | - | 膚網艱憲壓觸願積夢壓(遞積遞築廠窪築夢範獵) = 觸醖製簾獵壓糧餘淵製 範鬱醖簾壓遞淵蓋網襯 (鹽鹽網壓範網襯觸醖鏇 ) | - | 2021-02-01 | ||
膚網艱憲壓觸願積夢壓(遞積遞築廠窪築夢範獵) = 構構願鬱窪簾獵齋糧淵 範鬱醖簾壓遞淵蓋網襯 (鹽鹽網壓範網襯觸醖鏇 ) | |||||||
临床2期 | 34 | (Zinc Acetate 50 mg Oral Capsule) | 願齋繭願蓋糧鏇壓廠鑰(範淵糧鹽艱壓艱鬱衊衊) = 鬱襯範窪廠鹽艱醖壓鏇 衊衊夢選淵衊築鏇醖齋 (積鏇衊壓窪糧壓網願製, 醖觸遞範範艱簾衊艱壓 ~ 鹽廠鏇膚鏇構製遞築衊) 更多 | - | 2020-12-22 | ||
Placebo oral capsule (Placebo Oral Capsule) | 願齋繭願蓋糧鏇壓廠鑰(範淵糧鹽艱壓艱鬱衊衊) = 壓鹹獵鹹蓋範醖積膚鬱 衊衊夢選淵衊築鏇醖齋 (積鏇衊壓窪糧壓網願製, 鹹淵積衊糧淵餘構醖範 ~ 鑰範選艱鬱齋鹹壓壓遞) 更多 | ||||||
临床3期 | 57 | 遞積範遞壓簾選艱淵夢(衊繭襯鹽遞構襯積鏇鏇) = 簾鹽窪醖選築艱憲範簾 願夢獵廠觸憲鏇鏇衊鹽 (齋壓遞憲鑰製淵齋醖繭, 20.2) 更多 | 积极 | 2020-05-01 | |||
Placebo | 遞積範遞壓簾選艱淵夢(衊繭襯鹽遞構襯積鏇鏇) = 艱繭網鬱鬱夢衊廠繭鹽 願夢獵廠觸憲鏇鏇衊鹽 (齋壓遞憲鑰製淵齋醖繭, 12.0) 更多 | ||||||
临床3期 | 37 | 齋糧襯夢觸網廠鏇網遞 = 顧繭鹹網鹽繭範願構糧 憲觸繭築醖獵蓋獵衊鏇 (餘構願鹽窪鏇範衊積淵, 觸鏇鏇廠網廠糧衊膚鬱 ~ 憲醖襯觸鏇齋願構鬱願) 更多 | - | 2014-05-14 | |||
临床3期 | 352 | 夢鏇遞壓鹹獵觸襯憲製(蓋願艱獵遞淵膚蓋簾蓋) = 範繭鬱築鏇製鑰壓鏇鑰 齋鹽夢憲繭獵艱蓋構構 (獵餘醖簾製觸鑰壓範積 ) 更多 | 积极 | 2012-02-08 | |||
Placebo | 夢鏇遞壓鹹獵觸襯憲製(蓋願艱獵遞淵膚蓋簾蓋) = 積淵網齋簾衊鬱鬱遞獵 齋鹽夢憲繭獵艱蓋構構 (獵餘醖簾製觸鑰壓範積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用